Long-Term Clinical and Immunological Landscape Following Monkeypox Virus Infection and MVA-BN Vaccination: Insights from the Belgian MPX-COHORT and POQS-FU-PLUS Studies
Posted inClinical Updates Infectious Diseases news Public Health

Long-Term Clinical and Immunological Landscape Following Monkeypox Virus Infection and MVA-BN Vaccination: Insights from the Belgian MPX-COHORT and POQS-FU-PLUS Studies

This review synthesizes 24-month follow-up data on monkeypox virus infection and MVA-BN vaccination, detailing durable immunity post-infection, comparative antibody kinetics, and clinical sequelae, informing future vaccination strategies and patient management.
Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection
Posted inInfectious Diseases news

Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection

A post-hoc analysis of the BALANCE randomized trial shows that after accounting for treatment non-adherence using causal inference methods, 7 days of antibiotics for uncomplicated non‑Staphylococcus aureus bloodstream infection remains non‑inferior to 14 days for 90‑day mortality.
Targeted Vaccination Is Most Efficient but Not Cost‑Effective: National Serosurvey and Modelling of Japanese Encephalitis in Bangladesh
Posted inInfectious Diseases Neurology news Public Health

Targeted Vaccination Is Most Efficient but Not Cost‑Effective: National Serosurvey and Modelling of Japanese Encephalitis in Bangladesh

A nationally representative serosurvey and transmission modelling study in Bangladesh estimates low population-level JEV exposure but large numbers of infections annually; spatially targeted vaccination would be most efficient, though not cost-effective under conventional thresholds.
Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
Posted inCritical Care Infectious Diseases news Pediatrics Public Health Respiratory

Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications

A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlights stewardship and surveillance priorities.
再組合四價流感ワクチン（RIV4）は、9〜17歳の非劣性の免疫原性と許容可能な安全性を示す：第3相免疫ブリッジング試験の結果
Posted innews

再組合四價流感ワクチン（RIV4）は、9〜17歳の非劣性の免疫原性と許容可能な安全性を示す：第3相免疫ブリッジング試験の結果

第3相免疫ブリッジング試験では、再組合四価インフルエンザワクチン（RIV4）の単回投与が、9〜17歳の青少年において18〜49歳の成人に比べて非劣性のHAI反応を誘導し、同等の安全性プロファイルとより少ない所見反応を示した。
Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Posted inInfectious Diseases news Pediatrics

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study

A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited reactions in adolescents.
Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation
Posted inClinical Updates Infectious Diseases news Public Health Respiratory

Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation

This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the clinical impact of high-dose adjuvanted vaccines.
Efficacy and Implementation of a Digital Cognitive Behavioural Self-Management Programme (IBD-BOOST) for Fatigue, Pain, and Faecal Incontinence in Inflammatory Bowel Disease: A Comprehensive Review
Posted inClinical Updates Gastroenterology Neurology news

Efficacy and Implementation of a Digital Cognitive Behavioural Self-Management Programme (IBD-BOOST) for Fatigue, Pain, and Faecal Incontinence in Inflammatory Bowel Disease: A Comprehensive Review

This review evaluates the IBD-BOOST digital cognitive behavioural self-management intervention's design, trial outcomes, process evaluation, and clinical implications for managing fatigue, pain, and faecal incontinence in IBD.
Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes
Posted inHematology-Oncology news

Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes

A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGAT1 activity determine sensitivity—suggesting biomarker-guided repurposing strategies and combination approaches.
Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
Posted inCardiology Internal Medicine news

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit

A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit that persisted through several years of follow‑up.